Chronic hepatitis C. Predictive factors of response to treatment with interferon
López Alonso, G.
Anales de Medicina Interna 11(12): 573-574
1994
ISSN/ISBN: 0212-7199 PMID: 7537545 Document Number: 432872
Document emailed within 1 workday
Related Documents
Ishibashi, K.; Kashiwagi, T.; Ito, A.; Tanaka, Y.; Nagata, T.; Tamaki, J.; Azuma, M.; Kishida, Y.; Yoshida, A.; Hikiji, A.Y. 1995: Predictive factors for efficacy of interferon therapy in chronic hepatitis type C Hepato-Gastroenterology 42(5): 535-541Awan, A.; Umar, M.; Khaar, H.tul.Bushra.; Kulsoom, A.; Minhas, Z.; Ambreen, S.; Habib, N.; Mumtaz, W.; Habib, F. 2016: Predictive Value of Early Viriological Response for Sustained Viriological Response in Chronic Hepatitis with Conventional Interferon Therapy Journal of Ayub Medical College Abbottabad: Jamc 28(1): 14-17
Bizid, S.; Ben Abdallah, H.; Kilani, I.; Mohamed, G.; Bouali, R.; Abdelli, N. 2013: Predictive factors of response to peginterferon and ribavirin in Tunisians patients with chronic hepatitis C: report of 141 cases La Tunisie Medicale 91(5): 327-331
Moulin, V.; Harzic, M.; Doll, J.; Dubeaux, B.; Ghnassia, J.C.; Andrieu, J. 1996: Predictive value of a rapid negativity of serum virus C viremia during treatment with interferon alpha in patients with chronic hepatitis C Pathologie-Biologie 44(5): 468-472
Lo Iacono, O. 2000: Factors that predict the response to interferon in patients with chronic hepatitis C: clinical management of individual patients Revista Espanola de Enfermedades Digestivas: Organo Oficial de la Sociedad Espanola de Patologia Digestiva 92(8): 485-494
Ali, S.; Nazir, G.; Khan, S.A.; Iram, S.; Fatima, F. 2010: Comparative therapeutic response to pegylated interferon plus ribavirin versus interferon alpha-2b in chronic hepatitis C patients Journal of Ayub Medical College Abbottabad: Jamc 22(4): 127-130
Xu, H-tao.; Xing, T-jing.; Li, H.; Ye, J. 2012: Association of T regulatory cells with natural course and response to treatment with interferon-α in patients with chronic hepatitis B infection Chinese Medical Journal 125(8): 1465-1468
Hrycewycz, N.; Sandres, K.; Barange, K.; Pascal, J.P.; Izopet, J.; Payen, J.L. 2001: Eradication of hepatitis C virus after 3 months of interferon and ribavirin treatment in an a interferon non-responder patient with chronic hepatitis C Gastroenterologie Clinique et Biologique 25(11): 1041-1042
Kokoreva, L.N.; Zmyzgova, A.V.; Shalygina, N.B. 1996: The interferon therapy of patients with chronic viral hepatitis: the factors affecting the treatment results Terapevticheskii Arkhiv 68(2): 10-14
Chen, J.-L.; Wang, L.; Yan, J.; Zhang, L.; Yu, H.; Fan, X.-L. 2007: Predictive factors of hepatitis B virus DNA negative conversion among patients with chronic hepatitis B during lamivudine therapy Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 21(3): 273-275
Hamidah, A.; Yong, J.F.; Zulkifli, H.I.; Jamal, R. 2002: Treatment of chronic hepatitis C virus infection with interferon alfa and ribavirin: sustained response in two patients with transfusion dependent thalassaemia Medical Journal of Malaysia 57(3): 353-356
Ouakaa-Kchaou, A.; Gargouri, D.; Kochlef, A.; Debbiche, A.; Elloumi, H.; Ghouma, M.; Kilani, A.; Romani, M.; Kharrat, J.; Ghorbel, A. 2011: Steatosis in chronic hepatitis C: prevalence and predictive factors La Tunisie Medicale 89(11): 830-836
Srivastava, S.; Bertagnolli, M.; Lewis, J.H. 2005: Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic Journal of the National Medical Association 97(12): 1703-1707
Carlo, C.; Daniela, P.; Giancarlo, C. 2003: Iron depletion and response to interferon in chronic hepatitis C Hepato-Gastroenterology 50(53): 1467-1471
Actis, G.C.; Maran, E.; Bonino, F.; Saracco, G.; Rosina, F.; Brunetto, M.R.; Baldi, M.; Rizzetto, M.; Verme, G.; Rocca, B. 1987: Patterns of natural killer cell function activation in response to interferon in chronic HBsAG positive hepatitis: relationship with the state of viral infection and with the early clinical response Journal of Biological Regulators and Homeostatic Agents 1(1): 45-50
Musch, E.; Högemann, B.; Gerritzen, A.; Fischer, H.P.; Wiese, M.; Kruis, W.; Malek, M.; Gugler, R.; Schmidt, G.; Huchzermeyer, H.; Gerlach, U.; Dengler, H.J.; Sauerbruch, T. 1998: Phase Ii clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B Hepato-Gastroenterology 45(24): 2282-2294
Martín-Vivaldi, R.; Nogueras, F.; Vignote, M.L.; Salmerón, J.; Aguilar, J.; Romero, M.; Andrade, R.; De la Mata, M.; Moreno, J.M.; Pérez, J.; García, G.; López de Hierro, M.; Gómez, F.; Palacios, A.; Otero, S.; Suárez, E.; Poyatos, A.; Quintero, D. 2000: Multicenter retrospective study of response to interferon in chronic hepatitis B Revista Espanola de Enfermedades Digestivas: Organo Oficial de la Sociedad Espanola de Patologia Digestiva 92(9): 561-572
Lobello, S.; Lorenzoni, U.; Vian, A.; Floreani, A.; Brunetto, M.R.; Chiaramonte, M. 1998: Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B: role of hepatitis B core antibody IgM titre in patient selection and treatment monitoring Journal of Viral Hepatitis 5(1): 61-66
Panasiuk, A.; Prokopowicz, D.; Zak, J. 2004: Immunological response in chronic hepatitis C virus infection during interferon alpha therapy Hepato-Gastroenterology 51(58): 1088-1092
Tang, X.; Xu, Y.; Yuan, X. 2001: Relationship between intrahepatic HCV-specific CTL activity and response to interferon therapy in chronic hepatitis C Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 15(4): 352-354